ObjectiveTo detect the expression of contactin-1 (CNTN1) gene in the breast cancer tissues and explore the relation between the expression and prognosis of patients with breast cancer. MethodsThe clinicopathologic data of 35 patients with breast cancer who met the inclusion criteria from January to June in 2015 in the Shaanxi Provincial Cancer Hospital were retrospectively collected. The Western blot and immunohistochemistry methods were used to detect the CNTN1 protein expressions in the 35 breast cancer tissues and their corresponding tissues adjacent to cancer and the reverse transcriptase-PCR method was used to detect the CNTN1 mRNA expression. The relation between the CNTN1 protein expression and 5-year overall survival (OS) was analyzed. ResultsThe positive rate and expression level of CNTN1 protein in the breast cancer tissues were higher than those in the tissues adjacent to cancer [65.7% (23/35) vs. 45.7% (16/35), χ2=8.235, P=0.003; 0.825±0.221 vs. 0.412±0.117, t=12.556, P<0.001], and the expression level of CNTN1 mRNA in the breast cancer tissue was also higher than that in the corresponding tissues adjacent to cancer (0.763±0.218 vs. 0.353±0.135, t=11.162, P<0.001). The positive rates of CNTN1 protein were higher in the patients with larger tumor diameter (>2 cm), lower differentiation, later TNM stage (stage Ⅲ+Ⅳ) and axillary lymph node metastasis (P<0.05). The median OS of 35 patients with breast cancer was 47.3 months, which was 36.2 months and 52.5 months in the patients with high CNTN1 expression and low CNTN1 expression (median expression of CNTN1 protein was 0.785 as critical value) respectively (χ2=4.052, P=0.049). ConclusionPreliminary results of this study suggest that overexpression of CNTN1 gene might play an important role in occurrence and progression of primary breast cancer and is related to prognosis of survival.
Objective To assess efficacy of mepivacaine on local anesthesia in dentistry and oral surgery and its safety. Methods Parallel group, stratified randomization, double blinded, muti-center clinical trial was designed. Two percent lidocaine with adrenaline in same cartridge was as control. Healthy patients with deep decay, pulpitis needed operative dentistry, or indication for extraction of the teeth, which located in the maxilla or front part of the mandible were included. Results Except 17 cases, 127 patients fulfilled inclusion criteria: 66 in treatment group and 61 in control group, dental filling for 60 and extraction for 67 cases, male 55 and female 72, average at 38.84 + 12.06 years. Submucous infiltration of 1.5 ml mepivacaine at labial or buccal side of the alveolar process produced onset of anesthesia in the median of 60 seconds which was same as that of lidocaine, anesthesia duration for 146.7 minutes with the median of 125 minutes, permitting painless filling or extractions. In the treatment group 81.82% freed of pain, while 15.15% had slight pain but received no extra local anesthetic for implementation of the treatment procedures, making the successful rate of 96.97%. In the mepivacaine group, 13.64% of the cases had transient elevation of the systolic pressure to the level of 145-162 mmHg, 8.33% diastolic pressure to the level of 91-93 mmHg. Only one case had transient palpitation in half minute after one minute injection of the drug with no medical care needed. All the cardiovascular reactions might result from adrenaline containing in the injections. Conclusion Mepivacaine is an effective, safe and reliable anesthetic agent for dentistry and oral surgery.